MedTrace Logo

Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study

NCT02718937 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-05-30

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the antiviral activity of oral BTA-C585 compared to placebo in healthy volunteers after intranasal challenge with RSV-A Memphis 37b virus.

Conditions

  • Respiratory Syncytial Virus (RSV) Infection

Interventions

DRUG

BTA-C585 oral capsule

DRUG

Matching placebo capsules

Sponsors & Collaborators

  • Biota Pharma Europe Limited

    lead INDUSTRY

Principal Investigators

  • Anna Novotney-Barry · Aviragen Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02718937 on ClinicalTrials.gov